Microbial resistance to conventional as well as newly introduced drugs
is a hallmark feature of several infectious diseases, notably tubercu
losis. It is hypothesized that the greater the selective pressure exer
ted by increasingly potent drugs, the more rapidly is an organism able
to adapt to a drug-containing environment. The roles of drug-containi
ng environments, and the immunological status of the host and bacteria
l molecular mechanisms of development of drug resistance to Mycobacter
ium tuberculosis have been examined and examples cited for implementat
ion of modified drug regimens in tuberculosis-control programmes. The
views expressed, albeit restricted to Mycobacterium tuberculosis, enco
urage consideration of drug regimens on a disease evolution basis as w
ell as understanding of the natural rules that govern development and
sustenance of drug resistance in the microbial world.